Characteristics of HLA-DRB1*04:01+ RA patients used for optimization, enumeration and phenotypic studies
| Demographic and clinical details | RA patients (n = 20) |
| Age, mean (SD) | 58 (13.7) |
| Female sex, n (%) | 15 (75) |
| Disease duration (y), median (i.q.r) | 2 (1.25-5.75) |
| ACPA+, n (%) | 15 (75) |
| Current smokers, n (%) | 8 (40) |
| Ever smokers, n (%) | 17 (85) |
| Disease activity (DAS4v-CRP), median (i.q.r) | 2.38 (1.58-3.0) |
| Treatment | |
| Methotrexate, n (%) | 13 (65) |
| Hydroxychloroquine, n (%) | 13 (65) |
| Sulfasalazine, n (%) | 8 (40) |
| Low dose prednisone, n (%) | 3 (15) |
| Leflunomide, n (%) | 2 (10) |
| Multiple antirheumatic drugs, n (%) | 14 (70) |
| No treatment (%) | 1 (5) |
| Demographic and clinical details | RA patients (n = 20) |
| Age, mean (SD) | 58 (13.7) |
| Female sex, n (%) | 15 (75) |
| Disease duration (y), median (i.q.r) | 2 (1.25-5.75) |
| ACPA+, n (%) | 15 (75) |
| Current smokers, n (%) | 8 (40) |
| Ever smokers, n (%) | 17 (85) |
| Disease activity (DAS4v-CRP), median (i.q.r) | 2.38 (1.58-3.0) |
| Treatment | |
| Methotrexate, n (%) | 13 (65) |
| Hydroxychloroquine, n (%) | 13 (65) |
| Sulfasalazine, n (%) | 8 (40) |
| Low dose prednisone, n (%) | 3 (15) |
| Leflunomide, n (%) | 2 (10) |
| Multiple antirheumatic drugs, n (%) | 14 (70) |
| No treatment (%) | 1 (5) |